Sandoz Gets New Global, U.S. CEOs: Will Flat Regional Structure Spark Growth?
Executive Summary
Sandoz's new CEO Jeff George is flattening out the firm's global organization to position sales groups closer to customers, and he's hired former Barr CEO Christine Mundkur to shape up the U.S. operation in reforms aimed at returning the world's second largest generics business to strong growth
You may also be interested in...
Business News In Brief
Sandoz names DeGolyer head of U.S. business: Sandoz appointed Don DeGolyer President of its U.S. business unit, replacing Christine Mundkur who is leaving to pursue other opportunities, the drug maker announced March 8. Mundkur served a short role at the company after leaving her position as chief executive of Barr to shape up Sandoz's U.S. operation and grow the generics business in early 2009 (1"The Pink Sheet," Feb. 16, 2009). DeGolyer most recently held the position of senior VP and head of U.S. Commercial Operations for Sandoz US. At the same time, Sandoz also appoints Richard Tremonte VP of U.S. Retail Sales and Marketing, from his post as senior director of marketing for Sandoz U.S., which he held after joining the company in 2007
Business News In Brief
Sandoz names DeGolyer head of U.S. business: Sandoz appointed Don DeGolyer President of its U.S. business unit, replacing Christine Mundkur who is leaving to pursue other opportunities, the drug maker announced March 8. Mundkur served a short role at the company after leaving her position as chief executive of Barr to shape up Sandoz's U.S. operation and grow the generics business in early 2009 (1"The Pink Sheet," Feb. 16, 2009). DeGolyer most recently held the position of senior VP and head of U.S. Commercial Operations for Sandoz US. At the same time, Sandoz also appoints Richard Tremonte VP of U.S. Retail Sales and Marketing, from his post as senior director of marketing for Sandoz U.S., which he held after joining the company in 2007
Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal
A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan